These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3909340)

  • 21. Clinical experience with aztreonam in Europe: a summary of studies in Belgium, England, Finland, Ireland, the Netherlands, Norway, Portugal, and Sweden.
    Norrby SR
    Rev Infect Dis; 1985; 7 Suppl 4():S836-9. PubMed ID: 2934788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical experience with aztreonam in the treatment of gram-negative bacteremia.
    Scully BE; Henry SA
    Rev Infect Dis; 1985; 7 Suppl 4():S789-93. PubMed ID: 3909338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of aztreonam in the treatment of severe bacterial infections.
    Romero-Vivas J; Rodríguez-Créixems M; Bouza E; Hellín T; Guerrero A; Martínez-Beltrán J; García de la Torre M
    Antimicrob Agents Chemother; 1985 Aug; 28(2):222-6. PubMed ID: 3834832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of aztreonam in the treatment of skeletal infections due to Pseudomonas aeruginosa.
    Conrad DA; Williams RR; Couchman TL; Lentnek AL
    Rev Infect Dis; 1991; 13 Suppl 7():S634-9. PubMed ID: 2068473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of low dose aztreonam in the treatment of moderate to severe gram-negative bacterial infections.
    Clergeot A; Steru D; Rosset MA; Carbon C
    J Antimicrob Chemother; 1989 May; 23(5):753-8. PubMed ID: 2759924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
    Rabinad E; Bosch-Perez A
    Chemotherapy; 1989; 35 Suppl 1():1-7. PubMed ID: 2659288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in the treatment of intra-abdominal infections.
    Birolini D; Moraes MF; de Souza OS
    Chemotherapy; 1989; 35 Suppl 1():49-57. PubMed ID: 2659290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aztreonam: the first monobactam.
    Neu HC
    Med Clin North Am; 1988 May; 72(3):555-66. PubMed ID: 3280906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aztreonam in the treatment of gram-negative bacterial meningitis.
    Lentnek AL; Williams RR
    Rev Infect Dis; 1991; 13 Suppl 7():S586-90. PubMed ID: 2068463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infections due to gram-negative bacteria: an overview.
    Neu HC
    Rev Infect Dis; 1985; 7 Suppl 4():S778-82. PubMed ID: 3909337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative clinical evaluation of aztreonam versus aminoglycosides in gram-negative septicaemia.
    Gudiol F; Pallarés R; Ariza X; Fernández-Viladrich P; Rufi G; Liñares J
    J Antimicrob Chemother; 1986 May; 17(5):661-71. PubMed ID: 3722035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aztreonam in the therapy of severe gram-negative infections.
    Davies A; Stone J; Hassan A; Quarty P; Green T
    Chemioterapia; 1987 Jun; 6(2 Suppl):389-90. PubMed ID: 3509455
    [No Abstract]   [Full Text] [Related]  

  • 33. Clinical experience with aztreonam.
    Stutman HR
    Pediatr Infect Dis J; 1989 Sep; 8(9 Suppl):S109-12; discussion S128-32. PubMed ID: 2682508
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of aztreonam in gram-negative pneumonia versus a therapeutic regimen that includes an aminoglycoside. Spanish Study Group.
    Marco V; Gobernado M; Santos M; Rabinad E
    Chemotherapy; 1989; 35 Suppl 1():81-8. PubMed ID: 2659295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical studies of aztreonam in Japan.
    Hara K; Kobayashi H; Nishiura T; Yura J; Saito A
    Rev Infect Dis; 1985; 7 Suppl 4():S810-24. PubMed ID: 3909341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of aztreonam in the treatment of patients with renal failure.
    Sion ML; Pyrpasopoulos M; Nicolaidis P; Papagianni C; Tsurutsoglu G
    Rev Infect Dis; 1991; 13 Suppl 7():S652-4. PubMed ID: 2068477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aztreonam.
    Childs SJ; Bodey GP
    Pharmacotherapy; 1986; 6(4):138-52. PubMed ID: 3534798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of aztreonam in the treatment of neonatal sepsis.
    Sklavunu-Tsurutsoglu S; Gatzola-Karaveli M; Hatziioannidis K; Tsurutsoglu G
    Rev Infect Dis; 1991; 13 Suppl 7():S591-3. PubMed ID: 2068464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aztreonam in the treatment of gram-negative meningitis and other gram-negative infections.
    Feris J; Moledina N; Rodriguez WJ; Khan WN; Puig J; Wiedermann BL; Ahmad S
    Chemotherapy; 1989; 35 Suppl 1():31-8. PubMed ID: 2731448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.